To determine the pharmacokinetics and pharmacodynamics of Nilotinib in individuals with PD, we designed a physiologically based population pharmacokinetic/pharmacodynamic (popPK/PD) study and measured plasma and CSF concentration of Nilotinib as well as DOPAC, HVA, total and oligomeric alpha‐synuclein and TREM2 levels. The gene discussed is SNCA; the disease is Parkinson disease.